Long-term Testis Cancer Survivors in Canada-Mortality Risks in a Large Population-based Cohort.
Secondary neoplasm
Survivorship
Testicular neoplasm
Journal
European urology open science
ISSN: 2666-1683
Titre abrégé: Eur Urol Open Sci
Pays: Netherlands
ID NLM: 101771568
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
accepted:
21
10
2020
entrez:
2
8
2021
pubmed:
3
8
2021
medline:
3
8
2021
Statut:
epublish
Résumé
Testis cancer (TC) patients are young with excellent cancer prognosis. Hence, the risk of late-onset treatment-related morbidity and mortality is of concern due to longer survival after treatment. We set to characterize long-term survival of TC patients through a Canadian population dataset. We used a population-based dataset, the Canadian Census Health and Environment Cohort (CanCHEC), to identify individuals diagnosed with TC between 1991 and 2010. We compared them with all other male individuals without TC. The primary outcome was mortality due to cardiovascular disease (CVD) or nontesticular malignancy. Mann-Whitney or chi-square test was used where applicable. Data were analyzed using a Cox proportional hazard model with and without matching. We identified 1950 individuals with TC. We compared them with 1 300 295 men with no TC. There were 335 deaths in the study group during the study period (17.2%) with a mean follow-up of 19.6 yr. TC patients were at increased risk of death from secondary malignancies (hazard ratio [HR] 1.63, 95% confidence interval [CI] 1.39-1.91; NS patients are at increased risk of CVD-related death, whereas seminoma patients are at increased risk of death from non-testis-related malignancies. We report long-term mortality following diagnosis of testis cancer. Nonseminoma patients have an increased risk of death from cardiovascular disease, while seminoma patients have an increased risk of death from secondary malignancies.
Sections du résumé
BACKGROUND
BACKGROUND
Testis cancer (TC) patients are young with excellent cancer prognosis. Hence, the risk of late-onset treatment-related morbidity and mortality is of concern due to longer survival after treatment.
OBJECTIVE
OBJECTIVE
We set to characterize long-term survival of TC patients through a Canadian population dataset.
DESIGN SETTING AND PARTICIPANTS
METHODS
We used a population-based dataset, the Canadian Census Health and Environment Cohort (CanCHEC), to identify individuals diagnosed with TC between 1991 and 2010. We compared them with all other male individuals without TC.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
METHODS
The primary outcome was mortality due to cardiovascular disease (CVD) or nontesticular malignancy. Mann-Whitney or chi-square test was used where applicable. Data were analyzed using a Cox proportional hazard model with and without matching.
RESULTS AND LIMITATIONS
CONCLUSIONS
We identified 1950 individuals with TC. We compared them with 1 300 295 men with no TC. There were 335 deaths in the study group during the study period (17.2%) with a mean follow-up of 19.6 yr. TC patients were at increased risk of death from secondary malignancies (hazard ratio [HR] 1.63, 95% confidence interval [CI] 1.39-1.91;
CONCLUSIONS
CONCLUSIONS
NS patients are at increased risk of CVD-related death, whereas seminoma patients are at increased risk of death from non-testis-related malignancies.
PATIENT SUMMARY
RESULTS
We report long-term mortality following diagnosis of testis cancer. Nonseminoma patients have an increased risk of death from cardiovascular disease, while seminoma patients have an increased risk of death from secondary malignancies.
Identifiants
pubmed: 34337478
doi: 10.1016/j.euros.2020.10.005
pii: S2666-1683(20)36361-8
pmc: PMC8317812
doi:
Types de publication
Journal Article
Langues
eng
Pagination
54-60Informations de copyright
Crown Copyright © 2020 Published by Elsevier B.V. on behalf of European Association of Urology.
Références
J Clin Oncol. 2004 Feb 15;22(4):640-7
pubmed: 14726503
Int J Epidemiol. 2013 Oct;42(5):1319-26
pubmed: 24013141
Br J Cancer. 2004 Feb 9;90(3):607-12
pubmed: 14760372
Urol Clin North Am. 2015 Aug;42(3):393-408
pubmed: 26216826
J Clin Oncol. 2015 Oct 1;33(28):3105-15
pubmed: 26240226
BJU Int. 2009 Nov;104(9 Pt B):1418-22
pubmed: 19840023
Br J Cancer. 2013 Jul 9;109(1):60-7
pubmed: 23660945
Urol Oncol. 2014 Jan;32(1):26.e9-15
pubmed: 23410944
Cancer. 2017 Oct 15;123(20):4057-4065
pubmed: 28708930
Eur Urol. 2018 Feb;73(2):262-270
pubmed: 28687143
J Urol. 2009 Feb;181(2):627-32; discussion 632-3
pubmed: 19091344
Clin Genitourin Cancer. 2018 Aug;16(4):e761-e769
pubmed: 29534941
J Clin Oncol. 2014 Oct 1;32(28):3085-92
pubmed: 25024068
Hematol Oncol Clin North Am. 2011 Jun;25(3):627-39, x
pubmed: 21570614
J Natl Cancer Inst. 1994 Jul 6;86(13):983-8
pubmed: 8007020
J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65
pubmed: 16174857
Anticancer Res. 2017 Feb;37(2):831-834
pubmed: 28179338
J Clin Oncol. 2006 Jan 20;24(3):467-75
pubmed: 16421423
Curr Opin Oncol. 2017 Jul;29(4):229-234
pubmed: 28463858
J Clin Oncol. 2010 Oct 20;28(30):4649-57
pubmed: 20855830
J Natl Cancer Inst. 1997 Oct 1;89(19):1429-39
pubmed: 9326912
J Clin Oncol. 2007 Oct 1;25(28):4370-8
pubmed: 17906202
Cancer Res. 1981 Sep;41(9 Pt 1):3275-80
pubmed: 6167346
Urol Oncol. 2010 Sep-Oct;28(5):504-9
pubmed: 19097812
J Natl Cancer Inst. 2002 Feb 6;94(3):182-92
pubmed: 11830608
J Clin Oncol. 2002 Aug 15;20(16):3484-94
pubmed: 12177110
Lancet Oncol. 2007 Sep;8(9):784-96
pubmed: 17714993
J Natl Cancer Inst. 2007 Apr 4;99(7):533-44
pubmed: 17405998
J Clin Oncol. 1997 Feb;15(2):594-603
pubmed: 9053482
J Natl Cancer Inst. 1995 Oct 18;87(20):1530-7
pubmed: 7563187